KILITCH vs WOCKPHARMA: Stock Comparison

KILITCH vs WOCKHARDTUpdated 2 Jul 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. KILITCH shows a lower P/E, faster revenue growth and lower leverage, while WOCKHARDT shows a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KILITCH leads 8; WOCKPHARMA leads 4 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KILITCHWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹630 Cr
₹33,908 Cr
P/E RatioKILITCH has the lower reading
20.22x
75.68x
P/B RatioKILITCH has the lower reading
2.17x
6.27x
EPSWOCKPHARMA has the higher reading
₹1.45
₹6.58
Book ValueContext only
₹79.19
₹325
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹33,908 Cr vs ₹630 Cr
P/E Ratio
KILITCH has a lower P/E
20.22x vs 75.68x
P/B Ratio
KILITCH has a lower P/B
2.17x vs 6.27x
EPS
WOCKPHARMA has higher earnings per share
₹6.58 vs ₹1.45
Revenue Growth (TTM YoY)
KILITCH has faster revenue growth
46.3% vs 26%
EPS Growth (TTM YoY)
KILITCH has faster EPS growth
26.5% vs 0%
Qtr Sales Growth
KILITCH has stronger quarterly sales growth
-8.84% vs -39.61%
Qtr Profit Growth
KILITCH has stronger quarterly profit growth
156.81% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKILITCHWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKILITCHWOCKPHARMA
Live Price₹196.99₹2,088.7
Day Change-4.15%7.08%
Volume1.36 L35.58 L
52-Week High₹439₹2,422.3
52-Week Low₹117.25₹1,086.7
Distance from 52W High-55.13%-13.77%

Valuation

MetricKILITCHWOCKPHARMA
Market Cap₹630 Cr₹33,908 Cr
P/E Ratio20.22x75.68x
P/B Ratio2.17x6.27x
EPS₹1.45₹6.58
Book Value₹79.19₹325
Dividend Yield0%0%

Growth

MetricKILITCHWOCKPHARMA
Revenue Growth (TTM YoY)46.3%26%
EPS Growth (TTM YoY)26.5%0%
Qtr Sales Growth-8.84%-39.61%
Qtr Profit Growth156.81%0%

Profitability & Leverage

MetricKILITCHWOCKPHARMA
ROE9.73%10.28%
ROCE8.32%10.37%
Net Margin12.81%3.3%
Operating Margin23.33%28.35%
Debt to Equity0.27x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKILITCHWOCKPHARMA
Promoter Holding63.77%49.08%
FII Holding0.12% 0.12 pp7.22% 0.13 pp
DII Holding0%9.24% 1.72 pp
Public Holding36.11% 0.11 pp34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KILITCH and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.